RxDoctor Payments Data

Carrie Caffey, MD

Family Medicine · Lubbock, TXNPI 1164556262

Payments from drug & device makers

$5,049in general payments, 2019–2025

Across 316 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$825
  • Lilly USA, LLC$490
  • Pfizer$404
  • Novo Nordisk$317
  • GSK$291
  • Supernus Pharmaceuticals, Inc.$239
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,049100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,049 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$82,458
Medicare patients
178
Services billed
2,101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide77$93,035
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$56,751
JardianceEmpagliflozin52$53,039
EliquisApixaban57$51,265
JanuviaSitagliptin Phosphate69$48,429
TrulicityDulaglutide22$31,989
OzempicSemaglutide20$24,538
RybelsusSemaglutide14$18,278
FarxigaDapagliflozin Propanediol21$16,394
Tresiba Flextouch U-200Insulin Degludec16$14,908
Humalog Kwikpen U-200Insulin Lispro15$14,572
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$14,393
LinzessLinaclotide13$7,371
Tresiba Flextouch U-100Insulin Degludec12$6,133
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$5,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$490$125,02499 claims
GSKTrelegy Ellipta$291$56,75177 claims
Boehringer IngelheimJardiance$27$53,03952 claims
PfizerEliquis$404$51,26557 claims
MerckJanuvia$90$48,42969 claims
Novo NordiskOzempic, Rybelsus$317$42,81634 claims
AstraZenecaFarxiga, Symbicort$156$20,16737 claims
AbbVieLinzess, Synthroid$825$9,78750 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →